Tashiro H, Takahashi I, Yamamura S, Ishikawa T, Yanaga K, Wakasugi K, Matsusaka T, Kume K
Dept. of Surgery, Matsuyama Red Cross Hospital.
Gan To Kagaku Ryoho. 1999 May;26(6):775-9.
Effects of DAC (doxifluridine (5'-DFUR), adriamycin (ADM), cyclophosphamide (CPA)) chemotherapy were evaluated in seven patients with advanced breast cancer. 5'-DFUR of 600 mg was orally daily, ADM of 40 mg/m2 was administered intravenously (bolus) at day 1 and CPA of 400 mg/m2 was administered intravenously (one shot) at day 1 and day 8. These were repeated as one cycle of 21 days. Two complete responses, three partial responses and two progressive diseases were obtained, and the response rate was 71% (95% confidence interval: 29-96%). The side-effects of more than grade 3 were observed in leucocytopenia (4/7), neutrocytopenia (6/7), anorexia (2/7), nausea or vomiting (2/7) and alopecia (6/7). These results suggest that DAC chemotherapy is a novel, attractive regimen for treatment of advanced breast cancer. The randomized clinical trial is required to elucidate the efficacy of 5-fluorouracil (5-FU) or its analogues and the significance of methods for their administration in management of patients with advanced breast cancer.
对7例晚期乳腺癌患者评估了DAC（去氧氟尿苷（5'-DFUR）、阿霉素（ADM）、环磷酰胺（CPA））化疗的效果。5'-DFUR每日口服600mg，ADM 40mg/m²于第1天静脉推注，CPA 400mg/m²于第1天和第8天静脉一次性注射。这些作为21天的一个周期重复进行。获得了2例完全缓解、3例部分缓解和2例疾病进展，缓解率为71%（95%置信区间：29 - 96%）。在白细胞减少（4/7）、中性粒细胞减少（6/7）、厌食（2/7）、恶心或呕吐（2/7）和脱发（6/7）方面观察到3级以上的副作用。这些结果表明，DAC化疗是一种治疗晚期乳腺癌的新型、有吸引力的方案。需要进行随机临床试验以阐明5-氟尿嘧啶（5-FU）或其类似物的疗效以及它们在晚期乳腺癌患者管理中的给药方法的意义。
